| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
In RAW264.7 cells, wogonin (0-50 μM, 24 hours) suppresses the production of pro-inflammatory cytokines (IL-6 and TNF-α) and central mediators (NO, PGE2) generated by LPS [1]. Wogonin at 100 μM for 24 hours causes MDA-MB-231 and MCF-7 to proliferate [2]. Wogonin (100 μM, 9–24 hours) causes MDA-MB-231 cells to proliferate [2]. μM, 48-96 hours) can cause G1 phase induction and secretion, as well as suppress the growth of U937 and HL-60 cells [5].
|
|---|---|
| ln Vivo |
In the MDA-MB-231 orthotopic model, wogonin (80 mg/kg, gavaged once every other day) inhibits the growth and metastasis of tumors [3]. In A549 cell xenograft models, wogonin (40 or 80 mg/kg, intraperitoneal injection, every three days) inhibits tumor growth and decreases Bcl-2/Bax distribution [4]. Wogonin can also inhibit the U937 xenograft model when administered intraperitoneally once daily for 14 days at a dose of 80 mg/kg.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: MDA-MB-231 cells Tested Concentrations: 100 μM Incubation Duration: 9-24 hrs (hours) Experimental Results: Increased expression of LC3-II and Beclin-1. Inhibits the phosphorylation levels of mTOR Ser2448 and p70S6K Ser-389. |
| Animal Protocol |
Animal/Disease Models: MDA-MB-231 orthotopic model [3]
Doses: 80 mg/kg administered Method: po (oral gavage), once every other day. Experimental Results: Inhibited tumor growth (46%) and metastasis in the brain, lungs, liver and bones. Increase the expression of E-cadherin at the original site and decrease the expression of MMP-9, vimentin and Twist1. |
| References |
[1]. Yang YZ, et al. Wogonoside displays anti-inflammatory effects through modulating inflammatory mediator expression using RAW264.7 cells. J Ethnopharmacol. 2013 Jun 21;148(1):271-6.
[2]. Sun Y, et al. Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway. Food Chem Toxicol. 2013 Jan;51:53-60. [3]. Yao Y, et al. Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer. J Exp Clin Cancer Res. 2017 Aug 3;36(1):103. [4]. Luo M, et al. Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction. Biomed Pharmacother. 2018 Oct;106:593-598. [5]. Chen Y, et al. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood. 2013 May 2;121(18):3682-91. |
| Molecular Formula |
C22H20O11
|
|---|---|
| Molecular Weight |
460.391
|
| Exact Mass |
460.1006
|
| CAS # |
51059-44-0
|
| SMILES |
O1[C@]([H])(C(=O)O[H])[C@]([H])([C@@]([H])([C@]([H])([C@]1([H])OC1C([H])=C(C2C(C([H])=C(C3C([H])=C([H])C([H])=C([H])C=3[H])OC=2C=1OC([H])([H])[H])=O)O[H])O[H])O[H])O[H]
|
| Synonyms |
Oroxindin Wogonoside
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~271.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1721 mL | 10.8604 mL | 21.7207 mL | |
| 5 mM | 0.4344 mL | 2.1721 mL | 4.3441 mL | |
| 10 mM | 0.2172 mL | 1.0860 mL | 2.1721 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
